# Modeling Chronic BaP Exposure in Bronchial Epithelial Cells Reveals Multi-Scale Drivers of Early Preneoplastic Reprogramming

**Authors:** Cristian Andrade-Madrigal, Cecilia Rojas-Fuentes, Javier Díaz-Mijares, Gloria M. Calaf, Pablo M. Santoro, Alejandro H. Corvalán, Francisca J. Medina, Cristian G. Torres, Paula Romero-Vicencio, Julio C. Tapia, Mónica L. Acevedo, Ricardo Soto-Rifo, Enrique Boccardo, Francisco Aguayo

PMC · DOI: 10.3390/cells15060566 · 2026-03-22

## TL;DR

Chronic exposure to benzo[a]pyrene in bronchial cells leads to preneoplastic changes through multiple biological pathways, without causing full cancer.

## Contribution

The study establishes a validated multi-omics platform linking chronic BaP exposure to early preneoplastic reprogramming in bronchial epithelial cells.

## Key findings

- Chronic BaP exposure induces genotoxic stress and transcriptional changes without causing tumorigenicity.
- RNA-seq reveals dose-dependent gene expression shifts affecting extracellular matrix, inflammation, and signaling pathways.
- Organotypic cultures show histological dysplasia and disrupted polarity, indicating preneoplastic reprogramming.

## Abstract

Chronic exposure to benzo[a]pyrene (BaP), a Group 1 IARC carcinogen, is a major driver of lung carcinogenesis; however, how sustained subcytotoxic exposure reprograms bronchial epithelium toward preneoplastic states remains poorly defined. Here, we subjected BEAS-2B human bronchial epithelial cells to 12 weeks of continuous BaP at environmentally relevant concentrations (0.1 and 1.0 µM) and interrogated the resulting phenotypes using an integrated multi-scale framework encompassing functional toxicology, RT-qPCR, RNA-seq, phospho-kinase/NF-κB arrays, and organotypic air–liquid interface (ALI) cultures. Cells maintained metabolic competence throughout, evidenced by sustained CYP1A1 and CYP1B1 induction at both acute (4 h) and chronic (12-week) timepoints, while accumulating genotoxic stress as demonstrated by dose-dependent nuclear γ-H2AX foci formation and ATM phosphorylation (Ser1981). RNA-seq revealed a dose-dependent transcriptional shift: 0.1 µM BaP yielded 119 differentially expressed genes (DEGs; |log2FC| ≥ 1, FDR < 0.05), whereas 1.0 µM generated 255 DEGs. Downregulated transcripts were enriched for extracellular matrix and cell-adhesion programs (COL14A1, ADAMTS2, CSMD3, CADM3), while upregulated genes encompassed inflammatory, calcium-signaling, and vesicle-trafficking modules (NFATC4, CSF2RA, SYT1, PCLO). Phospho-kinase/NF-κB arrays confirmed a p53/NF-κB signaling nexus, with concurrent activation of MAPK/ERK (Thr202/Tyr204) and PI3K/Akt (Ser473) pathways. Despite persistent genotoxic stress, cells did not acquire anchorage-independent growth and remained non-tumorigenic in vivo. Critically, ALI organotypic cultures derived from BaP-exposed cells exhibited histological dysplasia, nuclear pleomorphism, and disrupted apical-basal polarity. These findings mechanistically link chronic BaP exposure to an initiation-like preneoplastic state and establish a validated 2D/3D multi-omics platform for PAH-driven lung carcinogenesis research.

## Linked entities

- **Genes:** CYP1A1 (cytochrome P450 family 1 subfamily A member 1) [NCBI Gene 1543], CYP1B1 (cytochrome P450 family 1 subfamily B member 1) [NCBI Gene 1545], H2AXA (Histone superfamily protein) [NCBI Gene 837409], ATM (ATM serine/threonine kinase) [NCBI Gene 472], COL14A1 (collagen type XIV alpha 1 chain) [NCBI Gene 7373], ADAMTS2 (ADAM metallopeptidase with thrombospondin type 1 motif 2) [NCBI Gene 9509], CSMD3 (CUB and Sushi multiple domains 3) [NCBI Gene 114788], CADM3 (cell adhesion molecule 3) [NCBI Gene 57863], NFATC4 (nuclear factor of activated T cells 4) [NCBI Gene 4776], CSF2RA (colony stimulating factor 2 receptor subunit alpha) [NCBI Gene 1438], SYT1 (synaptotagmin 1) [NCBI Gene 6857], PCLO (piccolo presynaptic cytomatrix protein) [NCBI Gene 27445], TP53 (tumor protein p53) [NCBI Gene 7157], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Chemicals:** benzo[a]pyrene (PubChem CID 2336), BaP (PubChem CID 2336)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CYP1A1 (cytochrome P450 family 1 subfamily A member 1) [NCBI Gene 1543] {aka AHH, CP11, CYP1, CYPIA1, P1-450, P450-C}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, CMPK1 (cytidine/uridine monophosphate kinase 1) [NCBI Gene 51727] {aka CK, CMK, CMPK, UMK, UMP-CMPK, UMPK}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CYP1B1 (cytochrome P450 family 1 subfamily B member 1) [NCBI Gene 1545] {aka ASGD6, CP1B, CYPIB1, GLC3A, P4501B1}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, H2AX (H2A.X variant histone) [NCBI Gene 3014] {aka H2A.X, H2A/X, H2AFX}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, ATR (ATR checkpoint kinase) [NCBI Gene 545] {aka FCTCS, FRP1, MEC1, SCKL, SCKL1}, SLC7A11 (solute carrier family 7 member 11) [NCBI Gene 23657] {aka CCBR1, xCT}, ADA2 (adenosine deaminase 2) [NCBI Gene 51816] {aka ADGF, CECR1, IDGFL, PAN, SNEDS, VAIHS}, CADM3 (cell adhesion molecule 3) [NCBI Gene 57863] {aka BIgR, CMT2FF, IGSF4B, NECL1, Necl-1, TSLL1}, PCNA (proliferating cell nuclear antigen) [NCBI Gene 5111] {aka ATLD2}, ADAMTS2 (ADAM metallopeptidase with thrombospondin type 1 motif 2) [NCBI Gene 9509] {aka ADAM-TS2, ADAMTS-2, ADAMTS-3, EDSDERMS, NPI, PC I-NP}, AHR (aryl hydrocarbon receptor) [NCBI Gene 196] {aka FVH3, RP85, bHLHe76}, CSF2RA (colony stimulating factor 2 receptor subunit alpha) [NCBI Gene 1438] {aka CD116, CDw116, CSF2R, CSF2RAX, CSF2RAY, CSF2RX}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, SYT1 (synaptotagmin 1) [NCBI Gene 6857] {aka BAGOS, P65, SVP65, SYT}, COL14A1 (collagen type XIV alpha 1 chain) [NCBI Gene 7373] {aka UND}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PIR (pirin) [NCBI Gene 8544], CSMD3 (CUB and Sushi multiple domains 3) [NCBI Gene 114788], CHEK2 (checkpoint kinase 2) [NCBI Gene 11200] {aka CDS1, CHK2, HuCds1, LFS2, PP1425, RAD53}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, ZEB1 (zinc finger E-box binding homeobox 1) [NCBI Gene 6935] {aka AREB6, BZP, DELTAEF1, FECD6, NIL2A, PPCD3}, ATM (ATM serine/threonine kinase) [NCBI Gene 472] {aka AT1, ATA, ATC, ATD, ATDC, ATE}, PCLO (piccolo presynaptic cytomatrix protein) [NCBI Gene 27445] {aka ACZ, PCH3}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, NFATC4 (nuclear factor of activated T cells 4) [NCBI Gene 4776] {aka NF-AT3, NF-ATC4, NFAT3}, ALX1 (ALX homeobox 1) [NCBI Gene 8092] {aka CART1, FND3, HEL23}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, COL9A1 (collagen type IX alpha 1 chain) [NCBI Gene 1297] {aka DJ149L1.1.2, EDM6, MED, STL4}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, Pcna (proliferating cell nuclear antigen) [NCBI Gene 18538]
- **Diseases:** tumorigenic (MESH:D002471), Dysplasia (MESH:D015792), ALI (MESH:D004618), cytotoxic (MESH:D064420), immunodeficient (MESH:D007153), injury to (MESH:D014947), carcinogenesis (MESH:D063646), Lung cancer (MESH:D008175), inflammation (MESH:D007249), preneoplastic (MESH:D011230), epithelial disorganization (MESH:D009375), Cancer (MESH:D009369), SCID (MESH:D053632), NOD (MESH:D020191)
- **Chemicals:** F12 (MESH:C007782), paraformaldehyde (MESH:C003043), DAPI (MESH:C007293), eosin (MESH:D004801), Alexa Fluor 647 (MESH:C569686), agar (MESH:D000362), EDTA (MESH:D004492), amphotericin B. (MESH:D000666), Antimycotic Solution (-), aldehydes (MESH:D000447), hydrocortisone (MESH:D006854), citrate (MESH:D019343), calcium (MESH:D002118), streptomycin sulfate (MESH:D013307), penicillin G (MESH:D010400), ethanol (MESH:D000431), BaP (MESH:D001564), crystal violet (MESH:D005840), Triton X-100 (MESH:D017830), PAH (MESH:D011084), hematoxylin (MESH:D006416), CO2 (MESH:D002245), BPDE (MESH:D015123), glycine (MESH:D005998), water (MESH:D014867), paraffin (MESH:D010232), xylazine (MESH:D014991), Formaldehyde (MESH:D005557), 32P (MESH:C000615311), PBS (MESH:D007854), H&amp;E (MESH:D006371), DMSO (MESH:D004121), methanol (MESH:D000432)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** C for 2-3, C110A, M610A, N251A, Thr-Gln
- **Cell lines:** 3T3-J2 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_W667), Ad12 — Homo sapiens (Human), Plasma cell myeloma, Cancer cell line (CVCL_A634), BEAS-2B — Homo sapiens (Human), Transformed cell line (CVCL_0168), gamma — Homo sapiens (Human), Fibrosarcoma, Cancer cell line (CVCL_C0D3), SV40 — Rattus norvegicus (Rat), Transformed cell line (CVCL_WN19), CRL-3588 — Homo sapiens (Human), Transformed cell line (CVCL_9N36)

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025689/full.md

---
Source: https://tomesphere.com/paper/PMC13025689